董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Pravin U. Dugel | 男 | Executive Chairman,President and Chief Executive Officer | 62 | 未披露 | 未持股 | 2026-01-20 |
| Leslie J. Williams | 女 | Director | 66 | 15.35万美元 | 未持股 | 2026-01-20 |
| Seung Suh Hong | 男 | Director | 68 | 14.62万美元 | 未持股 | 2026-01-20 |
| Merilee Raines | 女 | Director | 70 | 16.03万美元 | 未持股 | 2026-01-20 |
| Adrienne L. Graves | 女 | Director | 71 | 未披露 | 未持股 | 2026-01-20 |
| Richard Lindstrom | 男 | Director | 78 | 15.87万美元 | 未持股 | 2026-01-20 |
| Charles Warden | 男 | Lead Independent Director | 57 | 20.12万美元 | 未持股 | 2026-01-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey S. Heier | 男 | Chief Scientific Officer | 65 | 22.21万美元 | 未持股 | 2026-01-20 |
| Pravin U. Dugel | 男 | Executive Chairman,President and Chief Executive Officer | 62 | 未披露 | 未持股 | 2026-01-20 |
| Donald Notman | 男 | Chief Financial Officer and Chief Operating Officer | 66 | 153.86万美元 | 未持股 | 2026-01-20 |
| Jason Robins | 男 | Interim Chief Financial Officer | 49 | 未披露 | 未持股 | 2026-01-20 |
| Sanjay Nayak | 男 | Chief Strategy Officer | -- | 未披露 | 未持股 | 2026-01-20 |
| Nadia Waheed | 女 | Chief Medical Officer | -- | 未披露 | 未持股 | 2026-01-20 |
| Peter K. Kaiser | 男 | Chief Development Officer | -- | 未披露 | 未持股 | 2026-01-20 |
| Todd D.C. Anderman | 男 | Chief Legal Officer and Secretary | -- | 未披露 | 未持股 | 2026-01-20 |
董事简历
中英对照 | 中文 | 英文- Pravin U. Dugel
-
Pravin U. Dugel自2017年3月起担任Aerpio的董事会成员。自1994年以来，他担任Retinal Consultants of Arizona的管理合伙人，也是spectrum Eye Institute的创始成员。他是Southern California罗斯基眼科研究所，Southern California大学凯克医学院的临床教授。他担任Acucela, Inc.的顾问委员会成员，以及MacuSight, Inc.、Alcon Surgical、Genentech和Novartis的科学顾问委员会成员。他还担任TrueVision Systems, Inc.的医疗顾问委员会成员，以及Opthea Limited的临床顾问委员会成员。他在加州大学洛杉矶分校医学院获得医学博士学位，在哥伦比亚大学获得学士学位。
Pravin U. Dugel has served as a member of Aerpio's board of directors since March 2017. Since 1994 Dr. Dugel has served as the Managing Partner of Retinal Consultants of Arizona and is a Founding Member of the Spectra Eye Institute. He is a Clinical Professor at the USC Roski Eye Institute, Keck School of Medicine at the University of Southern California. Dr. Dugel serves on the Advisory Board of Acucela, Inc. and as a member of the Scientific Advisory Board at MacuSight, Inc., Alcon Surgical, Genentech and Novartis. He also serves as a Member of the Medical Advisory Board at TrueVision Systems, Inc. and a Member of the Clinical Advisory Board at Opthea Limited. Dr. Dugel received his M.D. from UCLA School of Medicine and his BA from Columbia University. - Pravin U. Dugel自2017年3月起担任Aerpio的董事会成员。自1994年以来，他担任Retinal Consultants of Arizona的管理合伙人，也是spectrum Eye Institute的创始成员。他是Southern California罗斯基眼科研究所，Southern California大学凯克医学院的临床教授。他担任Acucela, Inc.的顾问委员会成员，以及MacuSight, Inc.、Alcon Surgical、Genentech和Novartis的科学顾问委员会成员。他还担任TrueVision Systems, Inc.的医疗顾问委员会成员，以及Opthea Limited的临床顾问委员会成员。他在加州大学洛杉矶分校医学院获得医学博士学位，在哥伦比亚大学获得学士学位。
- Pravin U. Dugel has served as a member of Aerpio's board of directors since March 2017. Since 1994 Dr. Dugel has served as the Managing Partner of Retinal Consultants of Arizona and is a Founding Member of the Spectra Eye Institute. He is a Clinical Professor at the USC Roski Eye Institute, Keck School of Medicine at the University of Southern California. Dr. Dugel serves on the Advisory Board of Acucela, Inc. and as a member of the Scientific Advisory Board at MacuSight, Inc., Alcon Surgical, Genentech and Novartis. He also serves as a Member of the Medical Advisory Board at TrueVision Systems, Inc. and a Member of the Clinical Advisory Board at Opthea Limited. Dr. Dugel received his M.D. from UCLA School of Medicine and his BA from Columbia University.
- Leslie J. Williams
-
Leslie J.Williams自2021年2月起担任我们的董事会成员。她在生物制药行业工作了25年，是一位经验丰富的生物技术首席执行官和董事会成员。她拥有医疗保健、管理、商业产品开发和市场营销经验。2010年，她创立了临床阶段生物技术公司Immusant，Inc.，并担任Immusant的董事，总裁兼首席执行官，直到2019年。此前，她曾担任Ventaira Pharmaceuticals公司的总裁兼首席执行官（2004年以来），在她的领导下，该公司成为肺部药物输送市场的重要参与者，直到2007年底被出售。在加入Ventaira之前，Williams女士是INO Therapeutics，Inc.的营销总监，其他经验包括在Merck和GSK担任商业职位，以及在Datex-Ohmeda（前身为Ohmeda，Inc.）的药物交付和监控经验。她曾担任Battelle Ventures公司的风险合伙人，在那里她采购和评估交易，并协助早期技术公司的战略、管理、业务开发和并购。她曾在几个私人，公共和非营利董事会任职。她目前是Accelerator Life Science Partners的运营合伙人，自2019年以来担任Ocular Therapeutics（“；OCUL”；）的董事会成员，自2011年以来担任生命科学领导者，自2018年以来担任生命科学护理，自2017年以来担任生命科学领导者的编辑顾问委员会成员。Williams女士拥有华盛顿大学John Olin商学院的工商管理硕士学位，以及爱荷华大学的护理学士学位。在进入该行业之前，她曾在杜克大学、弗吉尼亚医学院和爱荷华大学担任重症监护护士。
Leslie J. Williams,has served as a member of Windtree Therapeutics, Inc. Board since February 2021 and also serves as Windtree Therapeutics, Inc. Lead Independent Director, and as Chair of the Governance Committee and as a member of the Audit Committee. In 2021, she founded hC Bioscience, Inc., a discovery stage biotech company, and serves as Director, President and Chief Executive Officer. Prior to this, she spent 10 years at ImmusanT, Inc., a clinical stage biotechnology company, and she served as Director, President & Chief Executive Officer of ImmusanT until 2019. Prior to that, she was President and Chief Executive Officer of Ventaira Pharmaceuticals since 2004 and under her leadership the company became a significant player in the pulmonary drug-delivery market until it was sold at the end of 2007. Prior to Ventaira, Ms. Williams was director of marketing for INO Therapeutics, Inc. and additional experience includes commercial positions at Merck and GSK, and drug-delivery and -monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.). She was a venture partner at Battelle Ventures where she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A. She has served on several private, public and non-profit boards. In addition to serving as Chief Executive Officer at hC Bioscience, she serves on the Board of Ocular Therapeutix, Inc. since 2019, Life Science Leader since 2011, CSCRI since 2018, and Life Science Cares since 2017. Ms. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa. - Leslie J.Williams自2021年2月起担任我们的董事会成员。她在生物制药行业工作了25年，是一位经验丰富的生物技术首席执行官和董事会成员。她拥有医疗保健、管理、商业产品开发和市场营销经验。2010年，她创立了临床阶段生物技术公司Immusant，Inc.，并担任Immusant的董事，总裁兼首席执行官，直到2019年。此前，她曾担任Ventaira Pharmaceuticals公司的总裁兼首席执行官（2004年以来），在她的领导下，该公司成为肺部药物输送市场的重要参与者，直到2007年底被出售。在加入Ventaira之前，Williams女士是INO Therapeutics，Inc.的营销总监，其他经验包括在Merck和GSK担任商业职位，以及在Datex-Ohmeda（前身为Ohmeda，Inc.）的药物交付和监控经验。她曾担任Battelle Ventures公司的风险合伙人，在那里她采购和评估交易，并协助早期技术公司的战略、管理、业务开发和并购。她曾在几个私人，公共和非营利董事会任职。她目前是Accelerator Life Science Partners的运营合伙人，自2019年以来担任Ocular Therapeutics（“；OCUL”；）的董事会成员，自2011年以来担任生命科学领导者，自2018年以来担任生命科学护理，自2017年以来担任生命科学领导者的编辑顾问委员会成员。Williams女士拥有华盛顿大学John Olin商学院的工商管理硕士学位，以及爱荷华大学的护理学士学位。在进入该行业之前，她曾在杜克大学、弗吉尼亚医学院和爱荷华大学担任重症监护护士。
- Leslie J. Williams,has served as a member of Windtree Therapeutics, Inc. Board since February 2021 and also serves as Windtree Therapeutics, Inc. Lead Independent Director, and as Chair of the Governance Committee and as a member of the Audit Committee. In 2021, she founded hC Bioscience, Inc., a discovery stage biotech company, and serves as Director, President and Chief Executive Officer. Prior to this, she spent 10 years at ImmusanT, Inc., a clinical stage biotechnology company, and she served as Director, President & Chief Executive Officer of ImmusanT until 2019. Prior to that, she was President and Chief Executive Officer of Ventaira Pharmaceuticals since 2004 and under her leadership the company became a significant player in the pulmonary drug-delivery market until it was sold at the end of 2007. Prior to Ventaira, Ms. Williams was director of marketing for INO Therapeutics, Inc. and additional experience includes commercial positions at Merck and GSK, and drug-delivery and -monitoring experience at Datex-Ohmeda (formerly Ohmeda, Inc.). She was a venture partner at Battelle Ventures where she sourced and evaluated deals and assisted early-stage technology companies with strategy, management, business development and M&A. She has served on several private, public and non-profit boards. In addition to serving as Chief Executive Officer at hC Bioscience, she serves on the Board of Ocular Therapeutix, Inc. since 2019, Life Science Leader since 2011, CSCRI since 2018, and Life Science Cares since 2017. Ms. Williams holds an MBA from Washington University, John Olin School of Business, and a B.S. degree with honors in nursing from the University of Iowa. Before entering industry, she was a critical-care nurse at Duke University, Medical College of Virginia and at the University of Iowa.
- Seung Suh Hong
-
Seung Suh Hong，自2019年6月起担任Ocular Therapeutix董事会成员。洪博士自2023年4月起担任生物制药公司Rophibio的首席执行官。洪博士曾于2021年1月至2023年2月担任生物制药初创公司Cellemedy的总裁兼首席运营官，并于2020年4月至2023年3月在韩国担任生物制药公司Novelgen的副董事长。洪博士自2019年3月起担任多家生物制药公司的顾问。2002年4月至2021年3月，他在生物制药公司Celltrion Inc.担任过各种职务，包括2016年1月至2021年3月担任Celltrion Healthcare Japan总裁和高级顾问；2014年11月至2015年12月担任Celltrion Healthcare Co.，Ltd.总裁兼首席执行官；2002年4月至2014年11月担任研发总裁。洪博士在首尔国立大学获得农业化学学士学位、工业酶学硕士学位和酶学与发酵学博士学位。洪博士还参加了威斯康星大学麦迪逊分校的博士后研究。
Seung Suh Hong,has served as a member of Ocular Therapeutix, Inc. board of directors since June 2019. Dr. Hong has served as Chief Executive Officer of Rophibio, a biopharmaceutical company since April 2023. Dr. Hong has served as President and Chief Operating Officer of Cellemedy, a biopharmaceutical start-up company, from January 2021 to February 2023 as well as Vice Chairman for Novelgen, a biopharmaceutical company, since April 2020 to March 2023, in South Korea. Dr. Hong has served as a consultant to a number of biopharmaceutical companies since March 2019. From April 2002 to March 2021, he served in various capacities at Celltrion Inc., a biopharmaceutical company, including as President of Celltrion Healthcare Japan and Senior Advisor from January 2016 to March 2021; as President and Chief Executive Officer of Celltrion Healthcare Co., Ltd. from November 2014 to December 2015; and as President of Research and Development from April 2002 to November 2014. Dr. Hong received a B.S. in Agricultural Chemistry, a M.S. in Industrial Enzymology, and a Ph.D. in Enzymology and Fermentation from Seoul National University. Dr. Hong also participated in post-doctoral studies at the University of Wisconsin-Madison. - Seung Suh Hong，自2019年6月起担任Ocular Therapeutix董事会成员。洪博士自2023年4月起担任生物制药公司Rophibio的首席执行官。洪博士曾于2021年1月至2023年2月担任生物制药初创公司Cellemedy的总裁兼首席运营官，并于2020年4月至2023年3月在韩国担任生物制药公司Novelgen的副董事长。洪博士自2019年3月起担任多家生物制药公司的顾问。2002年4月至2021年3月，他在生物制药公司Celltrion Inc.担任过各种职务，包括2016年1月至2021年3月担任Celltrion Healthcare Japan总裁和高级顾问；2014年11月至2015年12月担任Celltrion Healthcare Co.，Ltd.总裁兼首席执行官；2002年4月至2014年11月担任研发总裁。洪博士在首尔国立大学获得农业化学学士学位、工业酶学硕士学位和酶学与发酵学博士学位。洪博士还参加了威斯康星大学麦迪逊分校的博士后研究。
- Seung Suh Hong,has served as a member of Ocular Therapeutix, Inc. board of directors since June 2019. Dr. Hong has served as Chief Executive Officer of Rophibio, a biopharmaceutical company since April 2023. Dr. Hong has served as President and Chief Operating Officer of Cellemedy, a biopharmaceutical start-up company, from January 2021 to February 2023 as well as Vice Chairman for Novelgen, a biopharmaceutical company, since April 2020 to March 2023, in South Korea. Dr. Hong has served as a consultant to a number of biopharmaceutical companies since March 2019. From April 2002 to March 2021, he served in various capacities at Celltrion Inc., a biopharmaceutical company, including as President of Celltrion Healthcare Japan and Senior Advisor from January 2016 to March 2021; as President and Chief Executive Officer of Celltrion Healthcare Co., Ltd. from November 2014 to December 2015; and as President of Research and Development from April 2002 to November 2014. Dr. Hong received a B.S. in Agricultural Chemistry, a M.S. in Industrial Enzymology, and a Ph.D. in Enzymology and Fermentation from Seoul National University. Dr. Hong also participated in post-doctoral studies at the University of Wisconsin-Madison.
- Merilee Raines
-
Merilee Raines ，一直担任Watts Water Technologies, Inc.的董事会成员。Raines女士被任命为TransMedics Group公司的董事会成员，TransMedics Group公司是一家从事器官移植治疗的医疗技术公司，自2021年1月1日起生效。她还担任审计委员会成员，并将成为主席，自2021年6月1日起生效。Raines女士还曾在Aranta Therapeutics，Inc.的董事会任职，Aranta Therapeutics，Inc.是一家生物制药公司，专注于宠物伴侣市场的许可、开发和商业化产品。Raines女士目前是Excelitas Technologies Corporation的董事会成员，Excelitas Technologies Corporation是一家私营的全球工业技术公司，提供传感和检测解决方案，并担任其审计委员会主席。Raines女士是Dead River Company的董事会成员，Dead River Company是一家私营能源产品分销商，并在其财务和风险管理委员会任职。Raines女士此前曾是Affymetrix, Inc.的董事会成员，Affymetrix, Inc.是一家生命科学产品和分子诊断产品的上市供应商，在2015年1月至2016年4月期间，赛默飞世尔科学公司收购了Affymetrix。Raines女士此前还曾在PetVet Care Centers LLC的董事会任职。Raines女士于2003年10月至2013年5月退休期间，曾担任爱德士，Inc.的首席财务官，主要向伴侣动物健康市场提供诊断和IT产品及服务。Raines女士是注册会计师非活跃状态。1977年，她获得了鲍登学院的数学学士学位。1979年，她获得了芝加哥大学的硕士学位。
Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago. - Merilee Raines ，一直担任Watts Water Technologies, Inc.的董事会成员。Raines女士被任命为TransMedics Group公司的董事会成员，TransMedics Group公司是一家从事器官移植治疗的医疗技术公司，自2021年1月1日起生效。她还担任审计委员会成员，并将成为主席，自2021年6月1日起生效。Raines女士还曾在Aranta Therapeutics，Inc.的董事会任职，Aranta Therapeutics，Inc.是一家生物制药公司，专注于宠物伴侣市场的许可、开发和商业化产品。Raines女士目前是Excelitas Technologies Corporation的董事会成员，Excelitas Technologies Corporation是一家私营的全球工业技术公司，提供传感和检测解决方案，并担任其审计委员会主席。Raines女士是Dead River Company的董事会成员，Dead River Company是一家私营能源产品分销商，并在其财务和风险管理委员会任职。Raines女士此前曾是Affymetrix, Inc.的董事会成员，Affymetrix, Inc.是一家生命科学产品和分子诊断产品的上市供应商，在2015年1月至2016年4月期间，赛默飞世尔科学公司收购了Affymetrix。Raines女士此前还曾在PetVet Care Centers LLC的董事会任职。Raines女士于2003年10月至2013年5月退休期间，曾担任爱德士，Inc.的首席财务官，主要向伴侣动物健康市场提供诊断和IT产品及服务。Raines女士是注册会计师非活跃状态。1977年，她获得了鲍登学院的数学学士学位。1979年，她获得了芝加哥大学的硕士学位。
- Merilee Raines has been a member of the Company's Board of Directors since 2018 and is a member of the Board's Audit Committee. Since 2011 Ms. Raines has been a member of the Board of Directors of Watts Water Technologies, Inc., a publicly traded manufacturer of products and systems focused on control, conservation and quality of water. She is currently a member of that company's Nominating and Corporate Governance Committee, and she serves as Chair of its Audit Committee. Ms. Raines was appointed to the Board of Directors of TransMedics Group, Inc., a medical technology company involved in organ transplant therapy, effective January 1 2021. She also serves as a member of the Audit Committee and will become the Chair effective June 1 2021. Ms. Raines also served on the Board of Directors of Aranta Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing products for the pet companion market, from 2014 until the company was acquired by Elanco Animal Health Incorporated in July 2019. Ms. Raines is currently a member of the Board of Directors of Excelitas Technologies Corporation, a privately held global industrial technology company providing sensing and detection solutions, and is Chair of its Audit committee. Ms. Raines is a member of the Board of Directors of Dead River Company, a privately held distributor of energy products and serves on its Finance and Risk Management committees. Ms. Raines was previously a member of the Board of Directors of Affymetrix, Inc., a publicly traded provider of life sciences products and molecular diagnostic products, from January 2015 to April 2016 when Thermo Fisher Scientific, Inc. acquired Affymetrix. Ms. Raines also previously served on the board of PetVet Care Centers LLC, a privately owned operator of a network of veterinary hospitals from April 2016 to February 2018 when KKR acquired PetVet. Ms. Raines served as Chief Financial Officer of IDEXX Laboratories, Inc., a publicly traded company providing diagnostic and IT products and services primarily to the companion animal health market, from October 2003 until her retirement in May 2013. Ms. Raines is a Certified Public Accountant inactive status. She received a Bachelor's Degree in Mathematics from Bowdoin College, in 1977. In 1979 she received her MBA from the University of Chicago.
- Adrienne L. Graves
-
Adrienne L. Graves， 哲学博士。2005年4月起，她担任董事会成员，2002至2010年，担任Santen Inc.，的总裁和首席执行官，该公司是Santen Pharmaceutical Co., Ltd.的美国子公司。她目前是Santen的战略顾问。1995年，她加入Santen Inc.担任临场事务副总裁，开创了公司在美国的临床发展。 加入Santen Inc.之前，1986年起，她在Alcon Laboratories, Inc., or Alcon担任了9年的高级科学家。1992年，她被任命为Alcon临床科学部门的助理董事，1993年，担任Alcon的国际眼科学董事。她是30多个研究报告的作者，以及多个专业协会的成员，包括视力与眼科学研究协会（Association for Research in Vision and Ophthalmology）、美国眼科学会（American Academy of Ophthalmology）、美国青光眼与女性眼科协会（American Glaucoma Society and Women in Ophthalmology）。她还是美国眼科学基金会学会（American Academy of Ophthalmology Foundation）、全美洲眼科学协会（Pan-American Association of Ophthalmology）、美国白内障和激光手术协会（ American Association for Cataract and Refractive Surgery）、青光眼研究基金会（Glaucoma Research Foundation）和布朗大学医学院公司委员会（Corporation Committee for the Brown University Medical School）的董事会成员。她还是青光眼女性领袖（Ophthalmic Women Leaders）的创始人之一。她在布朗大学（Brown University）以优异成绩获得心理学学士学位，在密西根大学（University of Michigan）获得心理学博士学位，在巴黎大学（University of Paris）完成视觉神经系统科学博士学位。
Adrienne L. Graves, Ph.D. has been a member of TearLab Corporation's Board since April 2005. From 2002 to 2010 Dr. Graves was President and Chief Executive Officer of Santen Inc. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., beginning in 1986 as a Senior Scientist. Dr. Graves was named Associate Director of Alcon's Clinical Science Division in 1992 and then Alcon's Director of International Ophthalmology in 1993. Dr. Graves is the author of over thirty research papers and is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. She also serves on the boards of the American Academy of Ophthalmology Foundation emeritus, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation, and the Corporation Committee for the Brown University Medical School. Dr. Graves also co-founded Ophthalmic Women Leaders. She received her BA in psychology with honors from Brown University, received her Ph.D. in psychobiology from the University of Michigan, and completed a postdoctoral fellowship in visual neuroscience at the University of Paris. - Adrienne L. Graves， 哲学博士。2005年4月起，她担任董事会成员，2002至2010年，担任Santen Inc.，的总裁和首席执行官，该公司是Santen Pharmaceutical Co., Ltd.的美国子公司。她目前是Santen的战略顾问。1995年，她加入Santen Inc.担任临场事务副总裁，开创了公司在美国的临床发展。 加入Santen Inc.之前，1986年起，她在Alcon Laboratories, Inc., or Alcon担任了9年的高级科学家。1992年，她被任命为Alcon临床科学部门的助理董事，1993年，担任Alcon的国际眼科学董事。她是30多个研究报告的作者，以及多个专业协会的成员，包括视力与眼科学研究协会（Association for Research in Vision and Ophthalmology）、美国眼科学会（American Academy of Ophthalmology）、美国青光眼与女性眼科协会（American Glaucoma Society and Women in Ophthalmology）。她还是美国眼科学基金会学会（American Academy of Ophthalmology Foundation）、全美洲眼科学协会（Pan-American Association of Ophthalmology）、美国白内障和激光手术协会（ American Association for Cataract and Refractive Surgery）、青光眼研究基金会（Glaucoma Research Foundation）和布朗大学医学院公司委员会（Corporation Committee for the Brown University Medical School）的董事会成员。她还是青光眼女性领袖（Ophthalmic Women Leaders）的创始人之一。她在布朗大学（Brown University）以优异成绩获得心理学学士学位，在密西根大学（University of Michigan）获得心理学博士学位，在巴黎大学（University of Paris）完成视觉神经系统科学博士学位。
- Adrienne L. Graves, Ph.D. has been a member of TearLab Corporation's Board since April 2005. From 2002 to 2010 Dr. Graves was President and Chief Executive Officer of Santen Inc. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories, Inc., beginning in 1986 as a Senior Scientist. Dr. Graves was named Associate Director of Alcon's Clinical Science Division in 1992 and then Alcon's Director of International Ophthalmology in 1993. Dr. Graves is the author of over thirty research papers and is a member of a number of professional associations, including the Association for Research in Vision and Ophthalmology, the American Academy of Ophthalmology, the American Glaucoma Society, and Women in Ophthalmology. She also serves on the boards of the American Academy of Ophthalmology Foundation emeritus, the American Association for Cataract and Refractive Surgery, the Glaucoma Research Foundation, and the Corporation Committee for the Brown University Medical School. Dr. Graves also co-founded Ophthalmic Women Leaders. She received her BA in psychology with honors from Brown University, received her Ph.D. in psychobiology from the University of Michigan, and completed a postdoctoral fellowship in visual neuroscience at the University of Paris.
- Richard Lindstrom
-
Richard Lindstrom，他是医学博士。他担任Ocular Therapeutix, Inc.的董事（2012年以来）。他是Minnesota Eye Consultants P.A。（眼保健服务供应商）的创始人、董事和主治医师（1989年以来）。他曾一直担任TearLab Corporation的董事会成员（2010年以来），也曾担任Onpoint Medical Diagnostics公司的董事会成员（从2010年到2013年）。他曾一直担任the Minnesota Lions Eye Bank的助理董事（1987年以来）。他是一些医疗设备和药品制造商的医学顾问，并服务于几家民营生命科学公司的董事会。他此前曾担任the International Society of Refractive Surgery、the International Intraocular Implant Society、the International Refractive Surgery Club、the American Society of Cataract and Refractive Surgery的总裁。从1980年到1989年，他曾担任the University of Minnesota的眼科教授，在那里他目前是荣誉退休的兼职教授。他持有the University of Minnesota的前医学研究学士学位、医学学士学位和医学博士学位。
Richard Lindstrom,has served as a member of Ocular Therapeutix, Inc. board of directors since 2012. Dr. Lindstrom is the founder and director and has been an attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. He has served as a member of the boards of directors of LENSAR Corporation, a medical device company, since February 2018; Harrow Health (formerly known as Imprimis Pharmaceuticals, Inc.), a pharmaceutical company, since January 2015; and Trukera Medical (formerly known as TearLab Corporation), a diagnostics company, since 2010 and served as a member of the board of directors of Onpoint Medical Diagnostics, Inc. from 2010 to 2013. Dr. Lindstrom served as associate director of the Minnesota Lions Eye Bank from 1987 to 2017 and as a trustee of the University of Minnesota Foundation for four terms. He is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several privately-held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery, the International Intraocular Implant Society, the International Refractive Surgery Club and the American Society of Cataract and Refractive Surgery. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently adjunct clinical professor emeritus. Dr. Lindstrom holds a B.A. in Pre-Medical Studies, a B.S. in Medicine and an M.D. from the University of Minnesota. - Richard Lindstrom，他是医学博士。他担任Ocular Therapeutix, Inc.的董事（2012年以来）。他是Minnesota Eye Consultants P.A。（眼保健服务供应商）的创始人、董事和主治医师（1989年以来）。他曾一直担任TearLab Corporation的董事会成员（2010年以来），也曾担任Onpoint Medical Diagnostics公司的董事会成员（从2010年到2013年）。他曾一直担任the Minnesota Lions Eye Bank的助理董事（1987年以来）。他是一些医疗设备和药品制造商的医学顾问，并服务于几家民营生命科学公司的董事会。他此前曾担任the International Society of Refractive Surgery、the International Intraocular Implant Society、the International Refractive Surgery Club、the American Society of Cataract and Refractive Surgery的总裁。从1980年到1989年，他曾担任the University of Minnesota的眼科教授，在那里他目前是荣誉退休的兼职教授。他持有the University of Minnesota的前医学研究学士学位、医学学士学位和医学博士学位。
- Richard Lindstrom,has served as a member of Ocular Therapeutix, Inc. board of directors since 2012. Dr. Lindstrom is the founder and director and has been an attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. He has served as a member of the boards of directors of LENSAR Corporation, a medical device company, since February 2018; Harrow Health (formerly known as Imprimis Pharmaceuticals, Inc.), a pharmaceutical company, since January 2015; and Trukera Medical (formerly known as TearLab Corporation), a diagnostics company, since 2010 and served as a member of the board of directors of Onpoint Medical Diagnostics, Inc. from 2010 to 2013. Dr. Lindstrom served as associate director of the Minnesota Lions Eye Bank from 1987 to 2017 and as a trustee of the University of Minnesota Foundation for four terms. He is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several privately-held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery, the International Intraocular Implant Society, the International Refractive Surgery Club and the American Society of Cataract and Refractive Surgery. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently adjunct clinical professor emeritus. Dr. Lindstrom holds a B.A. in Pre-Medical Studies, a B.S. in Medicine and an M.D. from the University of Minnesota.
- Charles Warden
-
Charles Warden，他担任Ocular Therapeutix, Inc.的董事会成员（2008年以来）。他曾一直担任Versant Ventures公司的管理合伙人（2004年以来）。任职Versant公司之前，他曾担任Schroder Ventures Life Sciences公司（现称为SV Life Sciences公司）的普通合伙人（从1996年到2004年）。此前，他曾担任Boston Capital Ventures公司的职员，以及Monitor Company的顾问。他任职于几家民营生命科学公司的董事会，也一直任职 ForSight Labs公司（一个眼科孵化器）、The Foundry（医疗设备孵化器）、The Innovation Factory（医疗器械孵化器）。他拥有Beloit College的经济学学士学位，以及哈佛大学（Harvard University）的工商管理硕士学位。
Charles Warden,has served as a member of Ocular Therapeutix, Inc. board of directors since 2008. Mr. Warden has served as a Managing Director at Versant Ventures since 2004. He also has served as the President and Chief Executive Officer of Aquea Health, Inc., a medical device company he co-founded, since January 2020. Prior to Versant, he was a General Partner at Schroder Ventures Life Sciences (now SV Life Sciences), where he worked from 1996 to 2004. Previously, Mr. Warden served as an associate with Boston Capital Ventures and as a consultant with Monitor Company. He serves or has served on the boards of numerous privately-held life sciences companies. Mr. Warden holds a B.A. in Economics and Classics from Beloit College and an M.B.A. from Harvard University. - Charles Warden，他担任Ocular Therapeutix, Inc.的董事会成员（2008年以来）。他曾一直担任Versant Ventures公司的管理合伙人（2004年以来）。任职Versant公司之前，他曾担任Schroder Ventures Life Sciences公司（现称为SV Life Sciences公司）的普通合伙人（从1996年到2004年）。此前，他曾担任Boston Capital Ventures公司的职员，以及Monitor Company的顾问。他任职于几家民营生命科学公司的董事会，也一直任职 ForSight Labs公司（一个眼科孵化器）、The Foundry（医疗设备孵化器）、The Innovation Factory（医疗器械孵化器）。他拥有Beloit College的经济学学士学位，以及哈佛大学（Harvard University）的工商管理硕士学位。
- Charles Warden,has served as a member of Ocular Therapeutix, Inc. board of directors since 2008. Mr. Warden has served as a Managing Director at Versant Ventures since 2004. He also has served as the President and Chief Executive Officer of Aquea Health, Inc., a medical device company he co-founded, since January 2020. Prior to Versant, he was a General Partner at Schroder Ventures Life Sciences (now SV Life Sciences), where he worked from 1996 to 2004. Previously, Mr. Warden served as an associate with Boston Capital Ventures and as a consultant with Monitor Company. He serves or has served on the boards of numerous privately-held life sciences companies. Mr. Warden holds a B.A. in Economics and Classics from Beloit College and an M.B.A. from Harvard University.
高管简历
中英对照 | 中文 | 英文- Jeffrey S. Heier
Jeffrey S. Heier, M.D.，2015年以来，他担任Ocular Therapeutix, Inc.董事会成员。1998年以来，他担任Ophthalmic Consultants of Boston（OCB，一个大型的多专业眼科实践，在马萨诸塞州波士顿地区有几个办公室）。2009年以来，他担任OCB的玻璃体视网膜服务主管。2011年以来，他担任OCB的视网膜的研究主管。2016年他被任命为联合总裁。2002年以来，他担任OCB/Tufts University School of Medicine的the Vitreoretinal Fellowship的联合主管。他担任the Boston Eye Surgery and Laser Center、the Cape Code Eye Surgery and Laser Center和the Plymouth Eye Surgery and Laser Center的合伙人。他是一些生物制药和医疗设备公司的顾问。他在一些专业组织担任领导职务，包括the New England Ophthalmological Society的主席、the Retinal Society的秘书和the American Society of Retina Specialists的执行委员会成员。他持有Brandeis University的生物学学士学位，以及Boston University School of Medicine的医学博士学位。
Jeffrey S. Heier,has served as a member of Ocular Therapeutix, Inc. board of directors since 2015. Since 1998, Dr. Heier has worked as a vitreoretinal specialist at Ophthalmic Consultants of Boston, or OCB, a large multi-specialty ophthalmology practice with several offices in the Boston, Massachusetts area. He has served as Co-President and Medical Director from 2016 to 2020, the Director of Vitreoretinal Service of OCB since 2009 and the Director of Retina Research at OCB since 2011. He has been a partner of the Boston Eye Surgery and Laser Center, the Cape Cod Eye Surgery and Laser Center, and the Plymouth Eye Surgery and Laser Center. Dr. Heier is an advisor or consultant to several biopharmaceutical and medical device companies. Dr. Heier also serves in leadership roles of several professional organizations including as Former President of the New England Ophthalmological Society, as President of the Retinal Society, and as an executive board member of the American Society of Retina Specialists. Dr. Heier holds a B.S. in Biochemistry from Brandeis University and an M.D. from the Boston University School of Medicine.- Jeffrey S. Heier, M.D.，2015年以来，他担任Ocular Therapeutix, Inc.董事会成员。1998年以来，他担任Ophthalmic Consultants of Boston（OCB，一个大型的多专业眼科实践，在马萨诸塞州波士顿地区有几个办公室）。2009年以来，他担任OCB的玻璃体视网膜服务主管。2011年以来，他担任OCB的视网膜的研究主管。2016年他被任命为联合总裁。2002年以来，他担任OCB/Tufts University School of Medicine的the Vitreoretinal Fellowship的联合主管。他担任the Boston Eye Surgery and Laser Center、the Cape Code Eye Surgery and Laser Center和the Plymouth Eye Surgery and Laser Center的合伙人。他是一些生物制药和医疗设备公司的顾问。他在一些专业组织担任领导职务，包括the New England Ophthalmological Society的主席、the Retinal Society的秘书和the American Society of Retina Specialists的执行委员会成员。他持有Brandeis University的生物学学士学位，以及Boston University School of Medicine的医学博士学位。
- Jeffrey S. Heier,has served as a member of Ocular Therapeutix, Inc. board of directors since 2015. Since 1998, Dr. Heier has worked as a vitreoretinal specialist at Ophthalmic Consultants of Boston, or OCB, a large multi-specialty ophthalmology practice with several offices in the Boston, Massachusetts area. He has served as Co-President and Medical Director from 2016 to 2020, the Director of Vitreoretinal Service of OCB since 2009 and the Director of Retina Research at OCB since 2011. He has been a partner of the Boston Eye Surgery and Laser Center, the Cape Cod Eye Surgery and Laser Center, and the Plymouth Eye Surgery and Laser Center. Dr. Heier is an advisor or consultant to several biopharmaceutical and medical device companies. Dr. Heier also serves in leadership roles of several professional organizations including as Former President of the New England Ophthalmological Society, as President of the Retinal Society, and as an executive board member of the American Society of Retina Specialists. Dr. Heier holds a B.S. in Biochemistry from Brandeis University and an M.D. from the Boston University School of Medicine.
- Pravin U. Dugel
Pravin U. Dugel自2017年3月起担任Aerpio的董事会成员。自1994年以来，他担任Retinal Consultants of Arizona的管理合伙人，也是spectrum Eye Institute的创始成员。他是Southern California罗斯基眼科研究所，Southern California大学凯克医学院的临床教授。他担任Acucela, Inc.的顾问委员会成员，以及MacuSight, Inc.、Alcon Surgical、Genentech和Novartis的科学顾问委员会成员。他还担任TrueVision Systems, Inc.的医疗顾问委员会成员，以及Opthea Limited的临床顾问委员会成员。他在加州大学洛杉矶分校医学院获得医学博士学位，在哥伦比亚大学获得学士学位。
Pravin U. Dugel has served as a member of Aerpio's board of directors since March 2017. Since 1994 Dr. Dugel has served as the Managing Partner of Retinal Consultants of Arizona and is a Founding Member of the Spectra Eye Institute. He is a Clinical Professor at the USC Roski Eye Institute, Keck School of Medicine at the University of Southern California. Dr. Dugel serves on the Advisory Board of Acucela, Inc. and as a member of the Scientific Advisory Board at MacuSight, Inc., Alcon Surgical, Genentech and Novartis. He also serves as a Member of the Medical Advisory Board at TrueVision Systems, Inc. and a Member of the Clinical Advisory Board at Opthea Limited. Dr. Dugel received his M.D. from UCLA School of Medicine and his BA from Columbia University.- Pravin U. Dugel自2017年3月起担任Aerpio的董事会成员。自1994年以来，他担任Retinal Consultants of Arizona的管理合伙人，也是spectrum Eye Institute的创始成员。他是Southern California罗斯基眼科研究所，Southern California大学凯克医学院的临床教授。他担任Acucela, Inc.的顾问委员会成员，以及MacuSight, Inc.、Alcon Surgical、Genentech和Novartis的科学顾问委员会成员。他还担任TrueVision Systems, Inc.的医疗顾问委员会成员，以及Opthea Limited的临床顾问委员会成员。他在加州大学洛杉矶分校医学院获得医学博士学位，在哥伦比亚大学获得学士学位。
- Pravin U. Dugel has served as a member of Aerpio's board of directors since March 2017. Since 1994 Dr. Dugel has served as the Managing Partner of Retinal Consultants of Arizona and is a Founding Member of the Spectra Eye Institute. He is a Clinical Professor at the USC Roski Eye Institute, Keck School of Medicine at the University of Southern California. Dr. Dugel serves on the Advisory Board of Acucela, Inc. and as a member of the Scientific Advisory Board at MacuSight, Inc., Alcon Surgical, Genentech and Novartis. He also serves as a Member of the Medical Advisory Board at TrueVision Systems, Inc. and a Member of the Clinical Advisory Board at Opthea Limited. Dr. Dugel received his M.D. from UCLA School of Medicine and his BA from Columbia University.
- Donald Notman
Donald Notman，自2017年9月起担任Ocular Therapeutix, Inc.首席财务官。诺特曼先生此前曾于2014年5月至2017年3月期间担任生物制药公司Thrasos Therapeutics，Inc.的高级副总裁兼首席财务官，并于2017年3月至2017年12月期间担任顾问。在加入Thrasos Therapeutics之前，他曾于2005年6月至2013年4月担任专注于医疗保健的投资银行Leerink Swann LLC的董事总经理兼私人资本市场主管。诺特曼先生获得了米德尔伯里学院的经济学学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
Donald Notman,has served as Ocular Therapeutix, Inc. Chief Financial Officer since September 2017. Mr. Notman previously served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, Inc., a biopharmaceutical company, from May 2014 until March 2017 and as a consultant from March 2017 to December 2017. Prior to joining Thrasos Therapeutics, he served as Managing Director and Head of Private Capital Markets of Leerink Swann LLC, an investment bank specializing in health care, from June 2005 to April 2013. Mr. Notman received a B.A. in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth College.- Donald Notman，自2017年9月起担任Ocular Therapeutix, Inc.首席财务官。诺特曼先生此前曾于2014年5月至2017年3月期间担任生物制药公司Thrasos Therapeutics，Inc.的高级副总裁兼首席财务官，并于2017年3月至2017年12月期间担任顾问。在加入Thrasos Therapeutics之前，他曾于2005年6月至2013年4月担任专注于医疗保健的投资银行Leerink Swann LLC的董事总经理兼私人资本市场主管。诺特曼先生获得了米德尔伯里学院的经济学学士学位和达特茅斯学院塔克商学院的工商管理硕士学位。
- Donald Notman,has served as Ocular Therapeutix, Inc. Chief Financial Officer since September 2017. Mr. Notman previously served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics, Inc., a biopharmaceutical company, from May 2014 until March 2017 and as a consultant from March 2017 to December 2017. Prior to joining Thrasos Therapeutics, he served as Managing Director and Head of Private Capital Markets of Leerink Swann LLC, an investment bank specializing in health care, from June 2005 to April 2013. Mr. Notman received a B.A. in Economics from Middlebury College and an M.B.A. from The Tuck School of Business at Dartmouth College.
- Jason Robins
Jason Robins，自2025年1月起担任公司财务高级副总裁，负责会计、报告、财务规划和分析以及企业规划等工作。从2020年10月到2024年12月，Robins先生担任Fusion Pharmaceuticals Inc.财务副总裁，该公司是一家生物制药公司，于2024年6月被阿斯利康收购。Robins先生获得了巴布森学院的理学学士学位、哈佛-麻省理工学院Health Sciences与技术分部的理学硕士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
Jason Robins,has served as the Company's Senior Vice President, Finance, since January 2025, where he has managed accounting, reporting, financial planning and analysis, and corporate planning. From October 2020 to December 2024, Mr. Robins served as Vice President, Finance, of Fusion Pharmaceuticals Inc., a biopharmaceutical company acquired by AstraZeneca in June 2024. Mr. Robins received a Bachelor of Science from Babson College, a Master of Science from the Harvard-MIT Division of Health Sciences and Technology, and a Master of Business Administration from the MIT Sloan School of Management.- Jason Robins，自2025年1月起担任公司财务高级副总裁，负责会计、报告、财务规划和分析以及企业规划等工作。从2020年10月到2024年12月，Robins先生担任Fusion Pharmaceuticals Inc.财务副总裁，该公司是一家生物制药公司，于2024年6月被阿斯利康收购。Robins先生获得了巴布森学院的理学学士学位、哈佛-麻省理工学院Health Sciences与技术分部的理学硕士学位以及麻省理工学院斯隆管理学院的工商管理硕士学位。
- Jason Robins,has served as the Company's Senior Vice President, Finance, since January 2025, where he has managed accounting, reporting, financial planning and analysis, and corporate planning. From October 2020 to December 2024, Mr. Robins served as Vice President, Finance, of Fusion Pharmaceuticals Inc., a biopharmaceutical company acquired by AstraZeneca in June 2024. Mr. Robins received a Bachelor of Science from Babson College, a Master of Science from the Harvard-MIT Division of Health Sciences and Technology, and a Master of Business Administration from the MIT Sloan School of Management.
- Sanjay Nayak
Sanjay Nayak，自2024年2月起担任Ocular Therapeutix, Inc.首席战略官。纳亚克博士此前曾于2017年4月至2024年2月担任专注于生物技术的私人投资基金Sentiv Capital的创始人和基金经理。在创立Sentiv Capital之前，Nayak博士是医疗保健咨询事务所AnalyzeRX LLC的创始人，并于2003年12月至2019年9月担任该公司总裁。在创立AnalyzeRx LLC之前，Nayak博士曾于2000年4月至2003年12月担任战略分析，医疗保健的董事。Nayak博士在印度孟买大学格兰特医学院获得工商管理硕士学位，并在德雷克塞尔大学获得药理学博士学位。
Sanjay Nayak,has served as Ocular Therapeutix, Inc. Chief Strategy Officer since February 2024. Dr. Nayak previously served as founder and fund manager of biotechnology-focused private investment fund Sentiv Capital from April 2017 to February 2024. Prior to founding Sentiv Capital, Dr. Nayak was the founder of AnalyzeRx LLC, a healthcare consulting practice, and served as its President from December 2003 to September 2019. Prior to founding AnalyzeRx LLC, Dr. Nayak served as a Director at Strategic Analysis, Healthcare, from April 2000 to December 2003. Dr. Nayak received his M.B.B.S. from Grant Medical College, University of Bombay, India and earned a Ph.D. in pharmacology from Drexel University.- Sanjay Nayak，自2024年2月起担任Ocular Therapeutix, Inc.首席战略官。纳亚克博士此前曾于2017年4月至2024年2月担任专注于生物技术的私人投资基金Sentiv Capital的创始人和基金经理。在创立Sentiv Capital之前，Nayak博士是医疗保健咨询事务所AnalyzeRX LLC的创始人，并于2003年12月至2019年9月担任该公司总裁。在创立AnalyzeRx LLC之前，Nayak博士曾于2000年4月至2003年12月担任战略分析，医疗保健的董事。Nayak博士在印度孟买大学格兰特医学院获得工商管理硕士学位，并在德雷克塞尔大学获得药理学博士学位。
- Sanjay Nayak,has served as Ocular Therapeutix, Inc. Chief Strategy Officer since February 2024. Dr. Nayak previously served as founder and fund manager of biotechnology-focused private investment fund Sentiv Capital from April 2017 to February 2024. Prior to founding Sentiv Capital, Dr. Nayak was the founder of AnalyzeRx LLC, a healthcare consulting practice, and served as its President from December 2003 to September 2019. Prior to founding AnalyzeRx LLC, Dr. Nayak served as a Director at Strategic Analysis, Healthcare, from April 2000 to December 2003. Dr. Nayak received his M.B.B.S. from Grant Medical College, University of Bombay, India and earned a Ph.D. in pharmacology from Drexel University.
- Nadia Waheed
Nadia Waheed，自2024年6月起担任Ocular Therapeutix, Inc.首席医疗官。自2011年以来，Waheed博士是一名获得委员会认证的视网膜专家，她一直担任塔夫茨大学医学院的眼科教授，并在那里维持她的任命。Waheed博士还担任波士顿图像阅读中心的董事会成员，以及iOlyx Pharmaceuticals的董事会成员，iOlyx Pharmaceuticals是一家私营生物制药公司。Waheed博士此前曾于2022年11月至2024年6月在Beacon Therapeutics担任首席医疗和发展官，Beacon Therapeutics是一家专注于导致视力丧失和失明的严重眼部疾病的生物技术公司。在加入Beacon之前，她曾于2019年12月至2022年7月在Gyroscope Therapeutics（一家致力于眼科基因疗法的生物技术公司）担任首席医疗和开发官、临床开发主管。Waheed博士在巴基斯坦阿迦汗大学医学院获得医学博士学位，在哈佛大学公共卫生学院获得医学硕士学位。Waheed博士完成了她在哈佛医学院/麻萨诸塞州眼耳医院的住院医师和视网膜研究金。
Nadia Waheed,has served as Ocular Therapeutix, Inc. Chief Medical Officer since June 2024. Since 2011, Dr. Waheed, who is a board-certified retina specialist, has been Professor of Ophthalmology at Tufts University Medical School, where she maintains her appointment. Dr. Waheed also serves as a member of the board of directors for the Boston Image Reading Center, as well as on the board of directors of iOlyx Pharmaceuticals which is a privately-held biopharmaceutical company. Dr. Waheed previously served as Chief Medical and Development Officer at Beacon Therapeutics, a biotechnology company focused on serious diseases of the eye that cause vision loss and blindness, from November 2022 to June 2024. Prior to joining Beacon, she served as Chief Medical and Development Officer, Head of Clinical Development at Gyroscope Therapeutics, a biotechnology company working on ophthalmic gene therapies, from December 2019 to July 2022. Dr. Waheed received her M.D. from the Aga Khan University Medical School in Pakistan and her M.P.H. from the Harvard School of Public Health. Dr. Waheed completed her residency and retina fellowship at the Harvard Medical School / Massachusetts Eye and Ear Infirmary.- Nadia Waheed，自2024年6月起担任Ocular Therapeutix, Inc.首席医疗官。自2011年以来，Waheed博士是一名获得委员会认证的视网膜专家，她一直担任塔夫茨大学医学院的眼科教授，并在那里维持她的任命。Waheed博士还担任波士顿图像阅读中心的董事会成员，以及iOlyx Pharmaceuticals的董事会成员，iOlyx Pharmaceuticals是一家私营生物制药公司。Waheed博士此前曾于2022年11月至2024年6月在Beacon Therapeutics担任首席医疗和发展官，Beacon Therapeutics是一家专注于导致视力丧失和失明的严重眼部疾病的生物技术公司。在加入Beacon之前，她曾于2019年12月至2022年7月在Gyroscope Therapeutics（一家致力于眼科基因疗法的生物技术公司）担任首席医疗和开发官、临床开发主管。Waheed博士在巴基斯坦阿迦汗大学医学院获得医学博士学位，在哈佛大学公共卫生学院获得医学硕士学位。Waheed博士完成了她在哈佛医学院/麻萨诸塞州眼耳医院的住院医师和视网膜研究金。
- Nadia Waheed,has served as Ocular Therapeutix, Inc. Chief Medical Officer since June 2024. Since 2011, Dr. Waheed, who is a board-certified retina specialist, has been Professor of Ophthalmology at Tufts University Medical School, where she maintains her appointment. Dr. Waheed also serves as a member of the board of directors for the Boston Image Reading Center, as well as on the board of directors of iOlyx Pharmaceuticals which is a privately-held biopharmaceutical company. Dr. Waheed previously served as Chief Medical and Development Officer at Beacon Therapeutics, a biotechnology company focused on serious diseases of the eye that cause vision loss and blindness, from November 2022 to June 2024. Prior to joining Beacon, she served as Chief Medical and Development Officer, Head of Clinical Development at Gyroscope Therapeutics, a biotechnology company working on ophthalmic gene therapies, from December 2019 to July 2022. Dr. Waheed received her M.D. from the Aga Khan University Medical School in Pakistan and her M.P.H. from the Harvard School of Public Health. Dr. Waheed completed her residency and retina fellowship at the Harvard Medical School / Massachusetts Eye and Ear Infirmary.
- Peter K. Kaiser
Peter K. Kaiser，自2024年10月起担任Ocular Therapeutix, Inc.首席开发官。Kaiser博士此前曾于2024年2月至2024年9月担任Ocular Therapeutix, Inc.医疗总监，并于2022年6月至2024年2月担任首席医疗顾问–视网膜。自2011年以来，Kaiser博士一直担任克利夫兰诊所勒纳医学院的眼科研究主席和眼科教授，并担任工作人员外科医生。自2024年以来，凯撒医生一直担任克利夫兰诊所的咨询人员。Kaiser博士自2023年9月起担任私营生物技术公司AAVantgarde Bio的董事会成员。Kaiser博士已当选，此前曾担任美国眼科学会年会的Retina亚专科日董事会主席，并担任美国视网膜专家协会的董事会成员，是Retina Society、Macula Society、EURETINA和美国眼科学会的成员。Kaiser博士获得了哈佛学院的A.B.和哈佛医学院的医学博士学位。Kaiser博士在Bascom Palmer眼科研究所完成了他的玻璃体视网膜研究金。
Peter K. Kaiser,has served as Ocular Therapeutix, Inc. Chief Development Officer since October 2024. Dr. Kaiser previously served as Ocular Therapeutix, Inc. Medical Director from February 2024 until September 2024 and Chief Medical Advisor – Retina from June 2022 until February 2024. Since 2011, Dr. Kaiser has served as the chair of ophthalmology research and a professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine and as a staff surgeon. Since 2024, Dr. Kaiser has served as consulting staff at the Cleveland Clinic. Dr. Kaiser has served on the board of directors of AAVantgarde Bio, a privately-held biotechnology company, since September 2023. Dr. Kaiser has been elected and previously served as the Retina Subspecialty Day board chairman for the American Academy of Ophthalmology Annual Meeting, and as a member of the board of directors of the American Society of Retina Specialists, and is a member of the Retina Society, Macula Society, EURETINA and American Ophthalmological Society. Dr. Kaiser received an A.B. from Harvard College and an M.D. from Harvard Medical School. Dr. Kaiser completed his vitreoretinal fellowship at Bascom Palmer Eye Institute.- Peter K. Kaiser，自2024年10月起担任Ocular Therapeutix, Inc.首席开发官。Kaiser博士此前曾于2024年2月至2024年9月担任Ocular Therapeutix, Inc.医疗总监，并于2022年6月至2024年2月担任首席医疗顾问–视网膜。自2011年以来，Kaiser博士一直担任克利夫兰诊所勒纳医学院的眼科研究主席和眼科教授，并担任工作人员外科医生。自2024年以来，凯撒医生一直担任克利夫兰诊所的咨询人员。Kaiser博士自2023年9月起担任私营生物技术公司AAVantgarde Bio的董事会成员。Kaiser博士已当选，此前曾担任美国眼科学会年会的Retina亚专科日董事会主席，并担任美国视网膜专家协会的董事会成员，是Retina Society、Macula Society、EURETINA和美国眼科学会的成员。Kaiser博士获得了哈佛学院的A.B.和哈佛医学院的医学博士学位。Kaiser博士在Bascom Palmer眼科研究所完成了他的玻璃体视网膜研究金。
- Peter K. Kaiser,has served as Ocular Therapeutix, Inc. Chief Development Officer since October 2024. Dr. Kaiser previously served as Ocular Therapeutix, Inc. Medical Director from February 2024 until September 2024 and Chief Medical Advisor – Retina from June 2022 until February 2024. Since 2011, Dr. Kaiser has served as the chair of ophthalmology research and a professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine and as a staff surgeon. Since 2024, Dr. Kaiser has served as consulting staff at the Cleveland Clinic. Dr. Kaiser has served on the board of directors of AAVantgarde Bio, a privately-held biotechnology company, since September 2023. Dr. Kaiser has been elected and previously served as the Retina Subspecialty Day board chairman for the American Academy of Ophthalmology Annual Meeting, and as a member of the board of directors of the American Society of Retina Specialists, and is a member of the Retina Society, Macula Society, EURETINA and American Ophthalmological Society. Dr. Kaiser received an A.B. from Harvard College and an M.D. from Harvard Medical School. Dr. Kaiser completed his vitreoretinal fellowship at Bascom Palmer Eye Institute.
- Todd D.C. Anderman
Todd D.C. Anderman，自2024年10月起担任Ocular Therapeutix, Inc.首席法务官兼秘书。在加入Ocular Therapeutix之前，Anderman先生作为Anderman LLC的创始人和唯一成员（合法执业）于2024年2月至2024年9月期间为生物技术公司提供一般法律服务。他此前曾于2023年1月至2023年8月担任生物制药公司IVERIC bio，Inc.（IVERIC）高级副总裁、首席法务官和秘书；于2021年1月至2022年12月担任高级副总裁、总法律顾问和秘书；于2018年2月至2020年12月担任副总裁、总法律顾问和秘书，自2015年4月加入IVERIC以来自担任其他职务。在加入IVERIC之前，他曾于2012年4月至2015年4月在律师事务所Wilmer Cutler Pickering Hale和Dorr LLP的企业集团担任法律顾问和高级助理；并于2007年10月至2012年4月在同为律师事务所的Cravath，Swaine & Moore LLP的企业集团担任助理。Anderman先生在康奈尔大学文理学院获得政府和哲学学士学位，并在宾夕法尼亚大学法学院获得法学博士学位。
Todd D.C. Anderman,has served as Ocular Therapeutix, Inc. Chief Legal Officer and Secretary since October 2024. Prior to joining Ocular Therapeutix, Mr. Anderman provided general legal services to biotechnology companies from February 2024 to September 2024 as founder and sole member of Anderman LLC, a legal practice. He previously served as Senior Vice President, Chief Legal Officer and Secretary of IVERIC bio, Inc., or IVERIC, a biopharmaceutical company, from January 2023 until August 2023; as Senior Vice President, General Counsel and Secretary from January 2021 to December 2022; as Vice President, General Counsel and Secretary from February 2018 to December 2020 and in other roles since he joined IVERIC in April 2015. Prior to joining IVERIC, he served as a Counsel and a Senior Associate in the Corporate group of Wilmer Cutler Pickering Hale and Dorr LLP, a law firm, from April 2012 to April 2015; and an Associate in the Corporate group of Cravath, Swaine & Moore LLP, also a law firm, from October 2007 to April 2012. Mr. Anderman received a B.A. in Government and Philosophy from the College of Arts & Sciences at Cornell University and a J.D. from the University of Pennsylvania Law School.- Todd D.C. Anderman，自2024年10月起担任Ocular Therapeutix, Inc.首席法务官兼秘书。在加入Ocular Therapeutix之前，Anderman先生作为Anderman LLC的创始人和唯一成员（合法执业）于2024年2月至2024年9月期间为生物技术公司提供一般法律服务。他此前曾于2023年1月至2023年8月担任生物制药公司IVERIC bio，Inc.（IVERIC）高级副总裁、首席法务官和秘书；于2021年1月至2022年12月担任高级副总裁、总法律顾问和秘书；于2018年2月至2020年12月担任副总裁、总法律顾问和秘书，自2015年4月加入IVERIC以来自担任其他职务。在加入IVERIC之前，他曾于2012年4月至2015年4月在律师事务所Wilmer Cutler Pickering Hale和Dorr LLP的企业集团担任法律顾问和高级助理；并于2007年10月至2012年4月在同为律师事务所的Cravath，Swaine & Moore LLP的企业集团担任助理。Anderman先生在康奈尔大学文理学院获得政府和哲学学士学位，并在宾夕法尼亚大学法学院获得法学博士学位。
- Todd D.C. Anderman,has served as Ocular Therapeutix, Inc. Chief Legal Officer and Secretary since October 2024. Prior to joining Ocular Therapeutix, Mr. Anderman provided general legal services to biotechnology companies from February 2024 to September 2024 as founder and sole member of Anderman LLC, a legal practice. He previously served as Senior Vice President, Chief Legal Officer and Secretary of IVERIC bio, Inc., or IVERIC, a biopharmaceutical company, from January 2023 until August 2023; as Senior Vice President, General Counsel and Secretary from January 2021 to December 2022; as Vice President, General Counsel and Secretary from February 2018 to December 2020 and in other roles since he joined IVERIC in April 2015. Prior to joining IVERIC, he served as a Counsel and a Senior Associate in the Corporate group of Wilmer Cutler Pickering Hale and Dorr LLP, a law firm, from April 2012 to April 2015; and an Associate in the Corporate group of Cravath, Swaine & Moore LLP, also a law firm, from October 2007 to April 2012. Mr. Anderman received a B.A. in Government and Philosophy from the College of Arts & Sciences at Cornell University and a J.D. from the University of Pennsylvania Law School.